Skip to main content
Premium Trial:

Request an Annual Quote

Astute Medical Raises $6.2M in Series A Round

NEW YORK (GenomeWeb News) – Astute Medical said today that it has raised $6.2 million in a Series A round of financing led by De Novo Ventures.
 
San Diego-based Astute is developing protein biomarker-based tests for the rapid diagnosis and risk assessment of patients with hospital-acquired infections. The firm said it would use the funds from the first round of financing for research and development of the biomarkers.
 
Astute was founded last year and is led by CEO Christopher Hibberd, a former SVP of corporate development at Biosite, and CSO Paul McPherson, a former VP of research and development at Biosite, which was acquired last year for $1.7 billion by Inverness Medical Innovations.
 

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.